Compare PCB & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PCB | KALA |
|---|---|---|
| Founded | 2003 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 313.0M | 319.6M |
| IPO Year | 2018 | 2017 |
| Metric | PCB | KALA |
|---|---|---|
| Price | $21.93 | $0.31 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 3 |
| Target Price | $24.50 | ★ $31.50 |
| AVG Volume (30 Days) | 19.1K | ★ 696.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 4.00% | N/A |
| EPS Growth | N/A | ★ 41.50 |
| EPS | ★ 1.94 | N/A |
| Revenue | ★ $2,774,000.00 | N/A |
| Revenue This Year | $13.73 | N/A |
| Revenue Next Year | $9.07 | N/A |
| P/E Ratio | $11.35 | ★ N/A |
| Revenue Growth | ★ 4.68 | N/A |
| 52 Week Low | $16.02 | $0.26 |
| 52 Week High | $24.20 | $20.58 |
| Indicator | PCB | KALA |
|---|---|---|
| Relative Strength Index (RSI) | 40.79 | 35.92 |
| Support Level | $21.12 | N/A |
| Resistance Level | $22.30 | $0.72 |
| Average True Range (ATR) | 0.70 | 0.04 |
| MACD | -0.13 | -0.00 |
| Stochastic Oscillator | 32.56 | 42.26 |
PCB Bancorp is a bank holding company, which engages in the provision of consumer and commercial banking services. It provides Personal, Business, and Loan services, which provide banking, lending, and digital, tools, home loans, and others. Also, it offers a broad range of loans, deposits, and other products and services predominantly to small and middle-market businesses and individuals. The company provided it's services in Los Angeles and Orange Counties, California; Bellevue, Washington; and Atlanta, Georgia.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.